Share this page
Print this page
Email alert
CAL-101 SELECTED PUBLICATIONS & PRESENTATIONS
- Evidence of Clinical Activity in a Phase 1 Study of CAL-101, an Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. American Society of Hematology Annual Meeting, 12.8.09 (View Presentation)
- CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment American Society of Hematology Annual Meeting 12.7.09 (View Presentation)
CAL-101 is currently being investigated in clinical trials and has not received U.S. F.D.A. approval. Calistoga Pharmaceuticals does not claim that this technology or any of its product candidates are safe or will be effective in preventing, treating or curing any disease or condition.
